DAFTAR PUSTAKA

1. Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G. Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. Biomed Res Int. 2021;2021(1):1–14.
2. Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci. 2023;11(2):42.
3. Schutte HW, Heutink F, Wellenstein DJ, Broek GB Van Den, Hoogen FJA Van Den, Marres HAM, et al. Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic Review. 2020;
4. Köse G, Oz MD, Cömert E, Süzen HS. Association between superoxide dismutase 2, glutathione peroxidase 1, xeroderma pigmentosum group d gene variations, and head and neck squamous cell cancer susceptibility. Arch Biol Sci. 2022;74(2):181–9.
5. Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780–6.
6. Gold JM, Raja A. Cisplatin. StatPearls. 2023;1(1):1–9.
7. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, et al. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm. 2021;163(1):60–71.
8. Baguley DM, Prayuenyong P. Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy. Cancer Chemother Pharmacol. 2020;85(2):245–50.
9. Halani PD, Gupta RJ, Shah AM, Alurkar SS. Prospective Observational Study of Evaluating Cisplatin-Induced Ototoxicity in Patients. Indian J Med Paediatr Oncol. 2022;43(5):424–30.
10. Paken J, Govender CD, Pillay M, Feyasa M, Sewram V. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa. PLoS One. 2023;18(4):1–21.
11. Rahman S, Alviandi W, Edward Y, Firdaus MA, Machmud R. Gambaran Audiogram Nada Murni Penderita Karsinoma Kepala Dan Leher Yang Mendapat Satu Siklus Kemoterapi Cisplatin. Maj Kedokt Andalas. 2010;34(1):51–9.
12. Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity : A Challenge in Diagnosis and Treatment. 2018;22(2):59–68.
13. Rybak LP. Ototoxicity. In: Ballenger's Otorhinolaryngology Head and Neck Surgery. Wackym PA. Philadelphia; 2016. p. 311–6.
14. Fetoni AR, Paciello F, Troiani D. Cisplatin Chemotherapy and Cochlear Damage: Otoprotective and Chemosensitization Properties of Polyphenols. Antioxidants Redox Signal. 2022;36(16–18):1229–45.
15. Rhomdhoni AC, Kurniawan P, Hidayati T. Correlation Between Superoxide Dismutase Serum Level Alteration with Neck Metastatic Tumor Post Cisplatin–Paclitaxel Chemotherapy Response in Nasopharyngeal Carcinoma Patients. Indian J Otolaryngol Head Neck Surg. 2018;71:643–6.

16. Fetoni AR, Astolfi L. Cisplatin ototoxicity and role of antioxidant on its prevention. Hear Balanc Commun. 2020;18(4):234–41.
17. Sheth S, Mukherjea D, Rybak LP, Ramkumar V. Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection. 2017;11(October):1–12.
18. Rybak LP. Vestibular and Auditory Ototoxity. In: Flint PW, Robbins KT, Francis HW, Lesperance MM, Haughey BH LV, editor. Cummings Otolaryngology Head & Neck Surgery, seventh edition. 7th ed. Elsevier; 2021. p. 2370–80.
19. Yu D, Gu J, Chen Y, Kang W, Wang X, Wu H. Current Strategies to Combat Cisplatin-Induced Ototoxicity. Front Pharmacol. 2020;11(July):1–12.
20. Santos NAG dos, Ferreira RS, Santos AC dos. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 2020;136(1):1–19.
21. Gacek RR. Anatomy of the Auditory and Vestibular Systems. In: Ballenger's Otorhinolaryngology Head and Neck Surgery. 18 th. People's Medical Publishing House; 2016. p. 1–15.
22. Gale J, Forge A. Anatomy of the Cochlea and Vestibular System: Relating Ultrastructure to Function. In: Scott-Brown's Otorhinolaryngology Head and Neck Surgery, Volume 2 Paediatrics The Ear Skull Base. 2019. p. 545–66.
23. Maria PLS, Oghalai JS. Anatomy and Physiology of the Auditory System. In: Lalwani AK, editor. Sataloff's Comprehensive Textbook of Otolaryngology Head and Neck Surgery. First. New Delhi: Jaypee Brothers Medical Publishers; 2016. p. 1–18.
24. McGee J, Walsh EJ. Cochlear transduction and the molecular basis of auditory pathology.pdf. In: Cummings Otolaryngology Head and Neck Surgery 7th Ed. 7th ed. 2021. p. 2221–68.
25. Morrill S, He DZZ. Apoptosis in inner ear sensory hair cells. J Otol. 2017;12(4):151–64.
26. Xu K, Xu B, Gu J, Wang X, Yu D, Chen Y. Intrinsic mechanism and pharmacologic treatments of noise-induced hearing loss. Theranostics. 2023;13(11):3524–49.
27. Richard R Gacek. Anatomy of the Auditory and Vestibular Systems. In: Wackym PA, Snow JB, editors. Ballenger's Otorhinolaryngology Head And Neck Surgery. 18th ed. Shelton, CT: People's Medical Publishing House-USA; 2016. p. 1–16.
28. Dhingra P, Dhingra S. Peripheral Receptors and Physiology of Auditory and Vestibular Systems. In: Dhingra P, Dhingra S, editors. Disease of Ear, Nose, and Throat & Head and Neck Surgery. Seventh. New Delhi: Elsevier; 2018. p. 15–20.
29. Nyberg S, Abbott NJ, Shi X, Steyger PS, Dabdoub A. Delivery of therapeutics to the inner ear : The challenge of the blood-labyrinth barrier. Sci Transl Med. 2019;1(1):1–11.
30. Kishimoto-Urata M, Urata S, Fujimoto C, Yamasoba T. Role of Oxidative Stress and Antioxidants in Acquired Inner Ear Disorders. Antioxidants. 2022;11(8):1–23.
31. Toledo MM, De Souza Gonçalves B, Colodette NM, Chaves ALF, Muniz LV, Rosy Iara RIM, et al. Tumor Tissue Oxidative Stress Changes and Na,

K-ATPase Evaluation in Head and Neck Squamous Cell Carcinoma. J Membr Biol. 2021;254(5–6):475–86.
32. Huang G, Pan ST. ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer. Oxid Med Cell Longev. 2020;2020(1):1–30.
33. Alateyah N, Gupta I, Rusyniak RS, Ouhtit A. SOD2, a Potential Transcriptional Target Underpinning CD44-Promoted Breast Cancer Progression. Molecules. 2022;27(3):1–15.
34. Steyger PS. Mechanisms of Ototoxicity and Otoprotection. Otolaryngol Clin North Am. 2021;54(6):1101–15.
35. Joo Y, Cruickshanks KJ, Klein BEK, Klein R, Hong O, Wallhagen M. Prevalence of ototoxic medication use among older adults in Beaver Dam, Wisconsin. J Am Assoc Nurse Pract. 2018;30(1):27–34.
36. Watts KL. Ototoxicity: Visualized in Concept Maps. Semin Hear. 2019;40(2):177–87.
37. Forge A. Ototoxicity. In: Watkinson JC, Clarke RW, editors. Scott-Brown's Otorhinolaryngology and Head and Neck Surgery 8Ed. 2nd ed. London: Taylor & Francis Group, LLC; 2018. p. 721–37.
38. Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647–58.
39. Patatt FSA, Gonçalves LF, Paiva KM de, Haas P. Ototoxic effects of antineoplastic drugs: a systematic review. Braz J Otorhinolaryngol. 2022;88(1):130–40.
40. Isaradisaikul SK, Chowsilpa S. Ototoxicity after chemoradiotherapy for nasopharyngeal carcinoma. Ann Nasopharynx Cancer. 2020;4(8):9–9.
41. Putri MH, Rahaju P, Indrasworo D. Hubungan ototoksisitas dan kemoterapi neoadjuvan pada karsinoma nasofaring berdasarkan ASHA, CTCAE, dan DPOAE. Oto Rhino Laryngol Indones. 2018;47(2):102.
42. Tilova MM. Pengaruh Terapi Cisplatin dan Paclitaxel dengan dan Tanpa Pemberian Ginkgo Biloba Terhadap Ambang Dengar dan Fungsi Sel Rambut Luar Koklea Penderita Karsinoma Nasofaring. Universitas Hasanuddin; 2021.
43. Prayuenyong P, Baguley DM, Kros CJ, Steyger PS. Preferential Cochleotoxicity of Cisplatin. Front Neurosci. 2021;15(July):1–8.
44. Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8(1).
45. Tan M. The effect of genistein on cisplatin induced ototoxicity and oxidative stress. Braz J Otorhinolaryngol. 2022;88(1):105–11.
46. Parwata IMOA. Antioksidan. I Made Oka. Parwata IMOA, editor. Bali; 2016. 1–54 p.
47. Maharani AI, Riskierdi F, Febriani I, Kurnia KA. Peran Antioksidan Alami Berbahan Dasar Pangan Lokal dalam Mencegah Efek Radikal Bebas. In: Prosiding SEMNAS BIO 2021 Universitas Negri Padang. Padang: Inovasi Riset Biologi dalam Pendidikan Pengembangan Sumber Daya Lokal; 2021. p. 390–9.
48. Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria J Med.

2018;54(4):287–93.
49. Younus H. Therapeutic potentials of superoxide dismutase. Int J Health Sci (Qassim). 2018;12(3):88–93.
50. Rosa AC, Corsi D, Cavi N, Bruni N, Dosio F. Superoxide dismutase administration: A review of proposed human uses. Molecules. 2021;26(7):1–40.
51. Zheng M, Liu Y, Zhang G, Yang Z, Xu W, Chen Q. The Applications and Mechanisms of Superoxide Dismutase in Medicine, Food, and Cosmetics. Antioxidants. 2023;12(9):1–20.
52. Goysal K. Kadar Superoxide Dismutase (Sod) Dengan Stadium Dan Tipe Histopatologi Kanker Ovarium Tipe Epitelial. Hasanuddin; 2022.
53. Fang B, Xiao H. Rapamycin alleviates cisplatin-induced ototoxicity in vivo. Biochem Biophys Res Commun. 2014;30(1):1–5.
54. Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-Associated Ototoxicity : A Review for the Health Professional. 2016;2016(1):1–14.
55. Sadzuka Y, Shoji T, Takino Y. Effect of Cisplatin on the activites of enzymes which protect against lipid peroxidation. Biochem Pharmacol. 1992;43(8):1872–5.
56. Mendoza-Núñez VM, Ruiz-Ramos M, Sánchez-Rodríguez MA, Retana-Ugalde R, Muñoz-Sánchez JL. Aging-related oxidative stress in healthy humans. Tohoku J Exp Med. 2007;213(3):261–8.
57. Bennett KOC, Dille MF. Applying U.S. National Guidelines for Ototoxicity Monitoring in Adult Patients: Perspectives on Patient Population, Service Gaps, Barriers and Solutions. Natl Cent Rehabil Audit Res. 2019;57:1–30.
58. Durrant JD, Campbell K, Fausti S, Guthrie OW, Jacobson G, Lonsbury-Martin BL, et al. American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. Am Acad Audiol. 2009;1–25.
59. Al Malky G. Audiological monitoring in ototoxicity - Are we doing enough? ENT Audiol News. 2016;25(5):92–4.
60. Dahlan MS. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. 3rd ed. Dewi J I, editor. Jakarta: Salemba Medika; 2005. 74–8 p.
61. Aupérin A. Epidemiology of head and neck cancers: An update. Curr Opin Oncol. 2020;32(3):178–86.
62. Nathania N, Dewi YA, Permana AD. Profile of Head and Neck Cancer Patients at Hasan Sadikin Hospital in 2013-2018. Oto Rhino Laryngol Indones. 2020;50(2):141–5.
63. Saputra R. Pengaruh Injeksi N-Asetilsistein Intratimpani sebagai Otoproteksi terhadap Ambang Dengar Penderita Tumor Kepala Leher yang Mendapat Kemoterapi Cisplatin. Andalas; 2023.
64. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. J Kesehat Andalas. 2016;5(1):90–6.
65. Supriyanto N, Permana OR, Cahyadi I. Karakteristik Pasien Keganasan Kepala Leher Di RSUD Waled Periode 2014-2018. Tunas Med J Kedokt dan Kesehat. 2020;6:70–5.
66. Ruback MJC, Galbiatti AL, Arantes LMRB, Marucci GH, Russo A, Ruiz-

Cintra MT, et al. Clinical and epidemiological characteristics of patients in the head and neck surgery department of a university hospital. Sao Paulo Med J. 2012;130(5):307–13.
67. Skórska KB, Płaczkowska S, Prescha A, Porębska I, Kosacka M, Pawełczyk K, et al. Serum total SOD activity and SOD1/2 concentrations in predicting all-cause mortality in lung cancer patients. Pharmaceuticals. 2021;14(11):1–18.
68. Reastuty R, Haryuna TSH. Correlation of SOD and MDA Expression in the Organ of Corti and Changes in the Function of Outer Hair Cells Measured by DPOAE Examination in Noise-Exposed Rat Cochlea. Reports Biochem Mol Biol. 2021;10(1):41–9.
69. Strycharz-Dudziak M, Kiełczykowska M, Drop B, Świątek Ł, Kliszczewska E, Musik I, et al. Total Antioxidant Status (TAS), Superoxide Dismutase (SOD), and Glutathione Peroxidase (GPx) in Oropharyngeal Cancer Associated with EBV Infection. Oxid Med Cell Longev. 2019;1(1):1–15.
70. Mohideen K, Chandrasekaran K, M K, T J, Dhungel S, Ghosh S. Assessment of Antioxidant Enzyme Superoxide Dismutase (SOD) in Oral Cancer: Systematic Review and Meta-Analysis. Hindawi. 2024;2024(1):1–14.
71. Aminullah Y, Naftali Z, Santosa D, Prajoko YW, Azam M, Susanto H, et al. Boosting Antioxidant Defense: The Effect of Astaxantin on Superoxidase Dismutase and Malondialdehyde Reduction in Patients with Head and Neck Cancer Receiving Cisplatin Chemotherapy. Asian Pac J Cancer Prev. 2024;25(10):3741–8.
72. Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Cancer Epidemiol. 2022;79(6):1–10.
73. Kalyanam B, Sarala N, Azeem Mohiyuddin S, Diwakar R. Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case series follow-up study. J Cancer Res Ther. 2018;14(5):1099–104.
74. Nasr WF, Abdelhady M, Elbary MES, Nada E. Treatment of Cisplatin-induced Ototoxicity by Intra-tympanic Corticosteroid Injection. Indian J Otol. 2018;23(3):261–5.
75. Cahyadi I, Dewi YA. Status Pendengaran pada Penderita Karsinoma Nasofaring. Kanker THT-KepalaLeher.info. 2014;23(2):1–13.
76. Zińczuk J, Maciejczyk M, Zaręba K, Romaniuk W, Markowski A, Kędra B, et al. Antioxidant barrier, redox status, and oxidative damage to biomolecules in patients with colorectal cancer. Can malondialdehyde and catalase be markers of colorectal cancer advancement? Biomolecules. 2019;9(10):1–17.
77. González-García JÁ, Nevado J, García-Berrocal JR, Sánchez-Rodríguez C, Trinidad A, Sanz R, et al. Endogenous protection against oxidative stress caused by cisplatin: Role of superoxide dismutase. Acta Otolaryngol. 2010;130(4):453–7.
78. Jalali MM, Saedi HS, Saadat F. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration. Eur Arch Oto-Rhino-Laryngology. 2022;279(6):2783–9.

79. Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, et al. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol (Madr). 2018;57(8):1075–83.
80. Brown AL, Lupo PJ, Okcu MF, Lau CC, Rednam S, Scheurer ME. Brown-2015- SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated.pdf. Cancer Med. 2015;11(4):1679–86.